Danaher Co. (NYSE:DHR) Shares Purchased by Palisade Asset Management LLC

Palisade Asset Management LLC raised its stake in Danaher Co. (NYSE:DHR) by 0.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 24,880 shares of the conglomerate’s stock after buying an additional 117 shares during the quarter. Palisade Asset Management LLC’s holdings in Danaher were worth $5,756,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of DHR. Banco Santander S.A. purchased a new position in Danaher during the 3rd quarter valued at about $683,000. First Citizens Bank & Trust Co. raised its position in shares of Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after buying an additional 149 shares during the last quarter. Cercano Management LLC raised its position in Danaher by 11.4% in the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after purchasing an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after buying an additional 96,395 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its stake in shares of Danaher by 4.8% during the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 103,984 shares of company stock valued at $25,997,094. 10.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on DHR shares. Royal Bank of Canada lifted their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Bank of America lifted their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Barclays boosted their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Danaher Price Performance

NYSE DHR traded up $0.79 during mid-day trading on Wednesday, hitting $249.55. The stock had a trading volume of 1,443,446 shares, compared to its average volume of 2,724,113. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The firm’s 50 day moving average is $248.27 and its 200 day moving average is $233.19. The stock has a market capitalization of $184.84 billion, a price-to-earnings ratio of 42.18, a PEG ratio of 3.82 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period last year, the business posted $2.36 EPS. Equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.